Gregory Rood

New Brunswick Scientific Co., Inc. manufactures and designs research equipment and bioreactors. The company was founded in 1946 and is headquartered in Edison, NJ.

Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Atempo, Inc. develops software for data protection, recovery management, and archiving needs. It offers backup and recovery, archiving, storage, and security solutions. The firm’s products include Atempo Time Navigator, a backup and recovery solution that offers protection and archival solution for heterogeneous environments; Atempo Live Backup, a data protection solution for desktops and laptops; and Atempo Digital Archive that offers long-term archiving of files and other digital assets. The company was founded in 1992 and is headquartered in Palo Alto, CA.

YourBio Health, Inc. develops health monitoring products. It is developing an array of products based on the company's proprietary TAP? (Touch Activated Phlebotomy) painless blood collection platform. The company was founded by Richard Rox Anderson, Joerg Lahann, Robert S. Langer Jr., Douglas A. Levinson and Samir Mitragotri in 2008 and is headquartered in Medford, MA.

S&P Ingredient Development LLC develops and produces low sodium salt. The company is headquartered in Minnetonka, MN.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Bechtel Corp. operates as an engineering, construction, and project management company. Its portfolio encompasses energy, transportation, communications, mining, oil and gas, and government services. The firm also raises finance from a host of international lenders including commercial banks, multilateral and bilateral lending institutions, export credit agencies, and the capital markets. The company was founded by Warren A. Bechtel in 1898 and is headquartered in San Francisco, CA.

Atempo SASU provides data management software. It offers petascale storage backup, data migration and data copy, end point protection, desktop and laptop protection. The company was founded in 1992 and is headquartered in Courtabeouf, France.

Forum Mondial de L'Economie engages in the foremost political, business and cultural organizations to shape global, regional and industry agendas. The company was founded by Klaus Schwab in 1971 and is headquartered in Cologny, Switzerland.

The World Economic Forum USA, Inc. operates an organization for economic reforms. The non-profit company is based in New York, NY.

Midori USA, Inc. develops cellulosic technology for conversion of biomass to fuels. It offers biomass barrier technology that melts and digests biomass into sugars with a solid, recyclable catalyst. The company was founded by J. M. Geremia and Brian Baynes in 2008 and is headquartered in Cambridge, MA.

Ohana Biosciences, Inc. operates early stage biotechnology firm. The company is headquartered in Cambridge, MA.

Cygnal Therapeutics, Inc. develops drugs for cancer, immunological diseases and regenerative processes. The company was founded by Noubar Afeyan, Avak Kahvejian and Jordi Mata-Fink in 2017 and is headquartered in Cambridge, MA.

Cogen Immune Medicine, Inc. develops immune modulation therapeutics which control immune system. Its platform includes therapeutics, vaccines, clinical decision making, and immune health. The company was founded by Noubar B. Afeyan in 2017 and is headquartered in Cambridge, MA.

Cobalt Biomedicine, Inc. engages in the development of therapeutic based drugs. The company was founded in 2017 and is headquartered in Cambridge, MA.

Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA.

Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA.

Invaio Sciences, Inc. operates as multi-platform technology company. The firm develops multi-platform technology company that unlocks the potential of planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges. The company was founded in 2018 and is headquartered in Cambridge, MA.

Montai Health, Inc. is a company that is using its pioneering AI-powered Conecta™ platform to develop Anthromolecule™ medicines that will treat and preempt chronic diseases to improve health outcomes for the 2 billion people worldwide living with these diseases. The company is based in Cambridge, MA. Montai Health is unlocking the potential of Anthromolecule™ chemistry with its pioneering AI-powered Conecta™ platform to develop breakthrough small-molecule medicines that will treat and preempt chronic diseases to improve health outcomes for the two billion people worldwide living with these diseases. The company was founded by Hok Hei Tam, Michael Wong, David Kolesky, Mary Margaret Hastings Georgiadis. Mary Margaret Hastings Georgiadis has been the CEO since incorporation.

Cellarity Inc. engages in the operation of platform to design medicines targeting the full cellular and molecular complexity of disease. The company was founded by Avak Kahvejian, James J. Collins, Noubar Afeyan, and Nicholas Plugis in 2017 and is headquartered in Cambridge, MA.

Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA.

Part of Sonata Therapeutics, Inc., Inzen Therapeutics, Inc. is discovering and developing a novel class of medicines based on thanokine biology. The company is based in Cambridge, MA. Thanokine biology offers the potential for unprecedented approaches to prevent and treat cancer, fibrotic disorders, immune-inflammatory disorders, metabolic disorders, and degenerative diseases. Inzen's thanokine product platform applies advances in mass spectrometry and machine learning, novel probes, unique assays, genetic and chemical biological technologies to characterize thanokine biology at scale and create drug candidates. Inzen Therapeutics harnesses signals of the cellular microenvironment to treat serious diseases. The company was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

Generate Biomedicines, Inc. is a drug generation company that has developed a machine learning-powered multimodality generative biology platform capable of generating new drugs on demand across a wide range of biologic modalities. Generate Biomedicines is based in Somerville, MA. The platform seamlessly integrates computational and wet lab capabilities, improving the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company's platform represents a potentially fundamental shift in what's possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. The company was founded in 2018 by Poorya Hosseini, Molly Gibson, Geoffrey von Maltzahn, Avak Kahvejian, Gevorg Grigoryan. Michael T. Nally has been the CEO of the company since 2018.

MIT Solve (MIT Solve) is a venture capital firm. The firm is headquartered in Cambridge, Massachusetts.

Alltrna is a biotech company that uses AI/ML tools to learn the language of tRNA and develop programmable molecules with therapeutic potential. Alltrna was founded in 2018 by Flagship Pioneering and is based in Cambridge, MA. The company aims to correct diseases by advancing a single tRNA medicine to treat a wide range of diseases with the same underlying genetic mutation. The company's CEOs are Michelle C. Werner and Lovisa Afzelius.

Profound Therapeutics is a company that is focused on discovering new medicines by expanding the human proteome. The company is based in Cambridge, MA. The company uses their platform, Profoundry, to identify and validate proteins and understand their therapeutic potential. This results in a growing database of novel proteins and their roles in health and disease. The company was founded in 2020 by Avak Kahvejian, who has been the CEO since then.

Ampersand Biomedicines is an American company that designs programmable medicines that work precisely where needed in the body and nowhere else. The company's computationally powered platform identifies ideal addresses for drug localization and informs the design of and-body™ therapeutics that have the optimal therapeutic effect. The result is smarter biologic medicines that target the site of disease without affecting healthy tissue or cells. Ampersand is enabling potent mechanisms to treat disease by creating and programming therapeutics that are more efficacious, without compromising on safety or tolerability. The company was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering. Jason Gardner has been the CEO of the company since 2023.

Indigo Ag, Inc. provides microbial solutions. The company was founded by Noubar Afeyan, David A. Berry, and Geoffrey von Maltzahn in 2013 and is headquartered in Charlestown, MA.